{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:54:50Z","timestamp":1781715290417,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012280","name":"Rare Disease Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012280","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis (CF) is a multi-system disease that is characterized by lung disease due to recurrent airway infection and inflammation. Endocrine complications, such as CF bone disease (CFBD), are increasingly identified as patients are living longer. The cause of CFBD is multifactorial with chronic systemic inflammation theorized to be a contributing factor. Thus, we attempted to identify inflammatory biomarkers that are associated with CFBD. We conducted a retrospective observational study of 56 adult patients with CF with an average percentage predictive forced expiratory volume in one second (ppFEV<jats:sub>1<\/jats:sub>) of 73.7% (standard deviation: 30.0) who underwent baseline serum analysis for osteoprotegerin (OPG) and pro-inflammatory biomarkers (IL-1\u03b2, IL-6, IL-8 and TNF-\u03b1), and had repeated dual-energy x-ray absorptiometry (DXA) scans separated by at least 2 years to examine correlations between serum biomarkers and bone mineral density (BMD) measurements. Univariate linear regression model analysis demonstrated that serum IL-1\u03b2 and IL-8, but not other pro-inflammatory markers, were negatively correlated with baseline BMD results. However, after accounting for confounding variables, only the relationship between IL-8 and left femoral neck BMD remained statistically significant. Additionally, IL-8 level was associated with BMD decline over time. These results suggest that IL-8 might play a unique role in the pathophysiology of CFBD relative to other pro-inflammatory cytokines but further study is warranted before firm conclusions can be made.<\/jats:p>","DOI":"10.1038\/s41598-021-94883-1","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T10:02:43Z","timestamp":1627466563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["IL-8 correlates with reduced baseline femoral neck bone mineral density in adults with cystic fibrosis: a single center retrospective study"],"prefix":"10.1038","volume":"11","author":[{"given":"Grace Y.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiah","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita","family":"Goshtasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Kalyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"94883_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","volume":"132","author":"BJ Rosenstein","year":"1998","unstructured":"Rosenstein, B. J. & Cutting, G. R. The diagnosis of cystic fibrosis: A consensus statement. Cystic Fibrosis Foundation Consensus Panel. J. Pediatr. 132, 589\u2013595 (1998).","journal-title":"J. Pediatr."},{"key":"94883_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","volume":"86","author":"J Paccou","year":"2010","unstructured":"Paccou, J., Zeboulon, N., Combescure, C., Gossec, L. & Cortet, B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: A systematic literature review with meta-analysis. Calcif. Tissue Int. 86, 1\u20137. https:\/\/doi.org\/10.1007\/s00223-009-9316-9 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"94883_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.arcped.2016.05.001","volume":"23","author":"C Braun","year":"2016","unstructured":"Braun, C., Bacchetta, J. & Reix, P. Insights into cystic fibrosis-related bone disease. Arch. Pediatr. 23, 857\u2013866. https:\/\/doi.org\/10.1016\/j.arcped.2016.05.001 (2016).","journal-title":"Arch. Pediatr."},{"key":"94883_CR4","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-015-3343-3","volume":"27","author":"J Jacquot","year":"2016","unstructured":"Jacquot, J., Delion, M., Gangloff, S., Braux, J. & Velard, F. Bone disease in cystic fibrosis: New pathogenic insights opening novel therapies. Osteoporos Int. 27, 1401\u20131412. https:\/\/doi.org\/10.1007\/s00198-015-3343-3 (2016).","journal-title":"Osteoporos Int."},{"key":"94883_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S2213-2600(13)70025-0","volume":"1","author":"BJ Plant","year":"2013","unstructured":"Plant, B. J., Goss, C. H., Plant, W. D. & Bell, S. C. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir. Med. 1, 164\u2013174. https:\/\/doi.org\/10.1016\/S2213-2600(13)70025-0 (2013).","journal-title":"Lancet Respir. Med."},{"key":"94883_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00774-014-0572-z","volume":"33","author":"S Sheikh","year":"2015","unstructured":"Sheikh, S., Gemma, S. & Patel, A. Factors associated with low bone mineral density in patients with cystic fibrosis. J. Bone Miner. Metab. 33, 180\u2013185. https:\/\/doi.org\/10.1007\/s00774-014-0572-z (2015).","journal-title":"J. Bone Miner. Metab."},{"key":"94883_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2265.2012.04484.x","volume":"78","author":"M Rana","year":"2013","unstructured":"Rana, M., Munns, C. F., Selvadurai, H., Briody, J. & Craig, M. E. The impact of dysglycaemia on bone mineral accrual in young people with cystic fibrosis. Clin. Endocrinol. (Oxf.) 78, 36\u201342. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04484.x (2013).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"94883_CR8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/jc.2004-1629","volume":"90","author":"RM Aris","year":"2005","unstructured":"Aris, R. M. et al. Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. Metab. 90, 1888\u20131896 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94883_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcf.2009.11.005","volume":"9","author":"L Le Heron","year":"2010","unstructured":"Le Heron, L. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. J. Cyst. Fibros 9, 69\u201372. https:\/\/doi.org\/10.1016\/j.jcf.2009.11.005 (2010).","journal-title":"J. Cyst. Fibros"},{"key":"94883_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1164\/rccm.201312-2144LE","volume":"189","author":"F Velard","year":"2014","unstructured":"Velard, F. et al. Cystic fibrosis and bone disease: Defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator. Am. J. Respir. Crit. Care Med. 189, 746\u2013748. https:\/\/doi.org\/10.1164\/rccm.201312-2144LE (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94883_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1164\/rccm.200512-1943OC","volume":"174","author":"EF Shead","year":"2006","unstructured":"Shead, E. F. et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 174, 306\u2013311 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94883_CR12","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1164\/ajrccm.162.5.2002100","volume":"162","author":"RM Aris","year":"2000","unstructured":"Aris, R. M. et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 162, 1674\u20131678. https:\/\/doi.org\/10.1164\/ajrccm.162.5.2002100 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94883_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1203\/00006450-199703000-00016","volume":"41","author":"GI Baroncelli","year":"1997","unstructured":"Baroncelli, G. I. et al. Bone demineralization in cystic fibrosis: Evidence of imbalance between bone formation and degradation. Pediatr. Res. 41, 397\u2013403. https:\/\/doi.org\/10.1203\/00006450-199703000-00016 (1997).","journal-title":"Pediatr. Res."},{"key":"94883_CR14","first-page":"151","volume":"35","author":"T Jakovska","year":"2014","unstructured":"Jakovska, T., Mecevska-Jovcevska, J., Petlickovski, A., Fustik, S. & Zorcec, T. Prevalence of low bone mass and vitamin D deficiency in pediatric and adult patients with cystic fibrosis in Republic of Macedonia. Pril (Makedon Akad. Nauk. Umet Odd Med Nauki) 35, 151\u2013158 (2014).","journal-title":"Pril (Makedon Akad. Nauk. Umet Odd Med Nauki)"},{"key":"94883_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00198-003-1388-1","volume":"14","author":"RM Greer","year":"2003","unstructured":"Greer, R. M. et al. Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: Comparison with healthy controls. Osteoporos Int. 14, 404\u2013411. https:\/\/doi.org\/10.1007\/s00198-003-1388-1 (2003).","journal-title":"Osteoporos Int."},{"key":"94883_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/path.4753","volume":"240","author":"M Delion","year":"2016","unstructured":"Delion, M. et al. Overexpression of RANKL in osteoblasts: A possible mechanism of susceptibility to bone disease in cystic fibrosis. J. Pathol. 240, 50\u201360. https:\/\/doi.org\/10.1002\/path.4753 (2016).","journal-title":"J. Pathol."},{"key":"94883_CR17","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1007\/s00198-016-3612-9","volume":"27","author":"D Gensburger","year":"2016","unstructured":"Gensburger, D. et al. Reduced bone volumetric density and weak correlation between infection and bone markers in cystic fibrosis adult patients. Osteoporos Int. 27, 2803\u20132813. https:\/\/doi.org\/10.1007\/s00198-016-3612-9 (2016).","journal-title":"Osteoporos Int."},{"key":"94883_CR18","first-page":"162","volume":"66","author":"ME Street","year":"2006","unstructured":"Street, M. E. et al. Analysis of bone mineral density and turnover in patients with cystic fibrosis: Associations between the IGF system and inflammatory cytokines. Horm. Res. 66, 162\u2013168 (2006).","journal-title":"Horm. Res."},{"key":"94883_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.11613\/bm.2013.007","volume":"23","author":"J Zupan","year":"2013","unstructured":"Zupan, J., Jeras, M. & Marc, J. Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochem. Med. (Zagreb) 23, 43\u201363. https:\/\/doi.org\/10.11613\/bm.2013.007 (2013).","journal-title":"Biochem. Med. (Zagreb)"},{"key":"94883_CR20","first-page":"20","volume":"20","author":"S Conroy","year":"2020","unstructured":"Conroy, S. & Murray, E. Let the question determine the methods: Descriptive epidemiology done right. Brit. J. Cancer 20, 20 (2020).","journal-title":"Brit. J. Cancer"},{"key":"94883_CR21","volume-title":"Causal Inferences: What If","author":"MA Hernan","year":"2020","unstructured":"Hernan, M. A. & Robins, J. M. Causal Inferences: What If (Chapman & Hall, 2020)."},{"key":"94883_CR22","unstructured":"R Core Team, R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing [Internet]. 2011."},{"key":"94883_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates, D., Machler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1\u201348 (2015).","journal-title":"J. Stat. Softw."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94883-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:55:29Z","timestamp":1670068529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94883-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94883"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94883-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK is the Vice President of Scientific Innovation at Qu Biologics, a Canadian clinical-stage biotechnology company. All other authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15405"}}